Shire Eating Disorder Drug Gets F.D.A. Priority
Shire’s ?hyperactivity drug Vyvanse will get a priority review in america to be a potential strategy for binge eating disorders, showing a willingness by U.S. regulators to consider novel tips on how to fight eating problems.
The U.S. Food and Drug Administration a while back approved Orexigen Therapeutics’s long-awaited obesity pill Contrave plus an advisory panel also backed Novo Nordisk’s injectable drug liraglutide for losing fat.
Dublin-based Shire, that is certainly being acquired by U.S. drugmaker AbbVie, said on Monday how the FDA was likely to give its decision on the new using of Vyvanse by February 2015.
Vyvanse is actually only approved for Attention-Deficit Hyperactivity Disorder.
